San Diego, CA—A real-time performance tracking system that monitors adherence to quality care metrics significantly improved adherence to quality standards over a 4-year period for 64 cancer centers participating in the Rapid Quality Reporting System (RQRS) “beta test,” according to researchers who are pioneering the program.[ Read More ]
ASCO’s 1st Quality Care Symposium
San Diego, CA—A multidisciplinary team approach for discussing end-of-life issues with patients reduces the use of the intensive care unit (ICU) without shortening survival time, researchers from the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University said at ASCO’s inaugural 2012 Quality Care Symposium.
Multidisciplinary Support in End-of-Life Decisions[ Read More ]
Cabozantinib (Cometriq; Exelixis) is the second drug ever to be approved by the FDA for the treatment of patients with metastatic medullary thyroid cancer. Cabozantinib is a kinase inhibitor that blocks the abnormal kinase proteins that are involved in the development and growth of medullary cancer cells. Patients should not eat for at least 2 hours before and 1 hour after taking cabozantinib. Cabozantinib received an orphan drug designation.[ Read More ]
San Diego, CA—Adherence to several quality care standards markedly improved in practices participating in ASCO’s Quality Oncology Practice Initiative (QOPI) over a 4-year period, according to a study presented at ASCO’s inaugural 2012 Quality Care Symposium.
QOPI Participation Enhances Performance
The findings indicate that the oncology practices that participate in the QOPI are able to document significant and rapid improvement in their overall performance. Approximately 15% of US oncology practices are now participating in the QOPI.[ Read More ]